200 related articles for article (PubMed ID: 8437634)
1. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
[TBL] [Abstract][Full Text] [Related]
3. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
4. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
5. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
[TBL] [Abstract][Full Text] [Related]
6. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin.
Arch Intern Med; 1994 Nov; 154(21):2484-91. PubMed ID: 7979845
[TBL] [Abstract][Full Text] [Related]
7. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
Fink MP
Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
[TBL] [Abstract][Full Text] [Related]
9. [Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis].
van Deventer SJ; van der Linden CJ; Roord JJ; Schellekens H; Schellekens JF
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):334-6. PubMed ID: 8437630
[No Abstract] [Full Text] [Related]
10. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.
Greenman RL; Schein RM; Martin MA; Wenzel RP; MacIntyre NR; Emmanuel G; Chmel H; Kohler RB; McCarthy M; Plouffe J
JAMA; 1991 Aug; 266(8):1097-102. PubMed ID: 1865542
[TBL] [Abstract][Full Text] [Related]
11. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
Smith CR; Straube RC; Ziegler EJ
Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
13. Projected impact of monoclonal anti-endotoxin antibody therapy.
Bates DW; Lee TH
Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
16. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
[TBL] [Abstract][Full Text] [Related]
17. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection.
Shum HP; Chan KC; Kwan MC; Yan WW
Hong Kong Med J; 2013 Dec; 19(6):491-7. PubMed ID: 23650198
[TBL] [Abstract][Full Text] [Related]
18. Survival in selected patients with gram-negative sepsis after adjunctive therapy with HA-1A.
van Dissel JT; van Furth R; Compier BA; Feuth HD; Frolich M
Lancet; 1993 Apr; 341(8850):959-60. PubMed ID: 8096292
[No Abstract] [Full Text] [Related]
19. Passive immunotherapy of gram-negative bacteremia, sepsis and septic shock.
Spapen HD; Diltoer M; Huyghens LP
Acta Clin Belg; 1993; 48(1):20-9. PubMed ID: 7684546
[TBL] [Abstract][Full Text] [Related]
20. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
Luce JM
Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
